Is pulmonary vascular disease reversible with PPAR ɣ agonists?
Sign Up to like & getrecommendations! Published in 2018 at "Microcirculation"
DOI: 10.1111/micc.12444
Abstract: Severe angio‐obliterative PAH remains a disease characterized by great morbidity and shortened survival. Unfortunately, the only currently available treatments for angio‐obliterative changes are palliative in the form of pulmonary vasodilators evolving from the phosphodiesterase inhibitor… read more here.
Keywords: ppar; ppar agonists; angio obliterative; vascular disease ... See more keywords